Literature DB >> 26508288

Competition, Selectivity and Efficacy of Analogs of A-84543 for Nicotinic Acetylcholine Receptors with Repositioning of Pyridine Nitrogen.

Adebowale E Ogunjirin1, Joseph M Fortunak1,2, LaVerne L Brown1, Yingxian Xiao3, Martha I Dávila-García4.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) play a crucial role in a number of clinically relevant mental and neurological pathways, as well as autonomic and immune functions. The development of subtype-selective ligands for nAChRs therefore is potentially useful for targeted therapeutic management of conditions where nAChRs are involved. We tested if selectivity for a particular nAChR subtype can be achieved through small structural modifications of a lead compound containing the nicotinic pharmacophore by changing the distance between the electronegative elements. For this purpose, analogs of A-84543 were designed, synthesized and characterized as potentially new nAChR subtype-selective ligands. Compounds were tested for their binding properties in rat cerebral cortical tissue homogenates, and subtype-selectivity was determined using stably transfected HEK cells expressing different nAChR subtypes. All compounds synthesized were found to competitively displace [(3)H]-epibatidine ([(3)H]EB) from the nAChR binding site. Of all the analogues, H-11MNH showed highest affinity for nAChRs compared to a ~ fivefold to tenfold lower affinity of A-84543. All other compounds had affinities >10,000 nM. Both A-84543 and H-11MNH have highest affinity for α2β2 and α4β2 nAChRs and show moderate affinity for β4- and α7-containing receptors. H-11MNH was found to be a full agonist with high potency at α3β4, while A-84543 is a partial agonist with low potency. Based on their unique pharmacological binding properties we suggest that A-84543 and its desmethylpyrrolidine analog can be useful as pharmacological ligands for studying nAChRs if selective pharmacological and/or genetic tools are used to mask the function of other receptors subtypes.

Entities:  

Keywords:  A-85380; Cerebral cortex; Epibatidine; H-11MNH; Nicotine; Saturation

Mesh:

Substances:

Year:  2015        PMID: 26508288      PMCID: PMC4741274          DOI: 10.1007/s11064-015-1705-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  52 in total

1.  Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors.

Authors:  J E Spang; S Bertrand; G Westera; J T Patt; P A Schubiger; D Bertrand
Journal:  Chem Biol       Date:  2000-07

2.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

3.  Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.

Authors:  Yingxian Xiao; Maryna Baydyuk; Haizhu Pearl Wang; Heather E Davis; Kenneth J Kellar
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

4.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

Authors:  J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric
Journal:  Neuropharmacology       Date:  1996-06       Impact factor: 5.250

5.  An isotopic rubidium ion efflux assay for the functional characterization of nicotinic acetylcholine receptors on clonal cell lines.

Authors:  R J Lukas; M J Cullen
Journal:  Anal Biochem       Date:  1988-11-15       Impact factor: 3.365

6.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

7.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling.

Authors:  A O Koren; A G Horti; A G Mukhin; D Gündisch; A S Kimes; R F Dannals; E D London
Journal:  J Med Chem       Date:  1998-09-10       Impact factor: 7.446

Review 8.  Diversity of native nicotinic receptor subtypes in mammalian brain.

Authors:  Michele Zoli; Francesco Pistillo; Cecilia Gotti
Journal:  Neuropharmacology       Date:  2014-11-25       Impact factor: 5.250

9.  T cells express alpha7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response.

Authors:  Seddigheh Razani-Boroujerdi; R Thomas Boyd; Martha I Dávila-García; Jayashree S Nandi; Neerad C Mishra; Shashi P Singh; Juan Carlos Pena-Philippides; Raymond Langley; Mohan L Sopori
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 10.  α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.

Authors:  Ramakrishna Nirogi; Venkatesh Goura; Renny Abraham; Pradeep Jayarajan
Journal:  Eur J Pharmacol       Date:  2013-05-07       Impact factor: 4.432

View more
  1 in total

1.  Site-Selective Switching Strategies to Functionalize Polyazines.

Authors:  Ryan D Dolewski; Patrick J Fricke; Andrew McNally
Journal:  J Am Chem Soc       Date:  2018-05-24       Impact factor: 15.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.